Are GLP-1 Medications Safe? What the FDA Data Shows in 2026

By Dr. Don Gates, MD, Founder of Scale Solutions

For appropriately selected patients, GLP-1 medications have one of the best-characterized safety profiles in outpatient medicine — not because they are gentle, but because they have been studied in an unusual number of people, and because regulators have kept investigating them after approval. The most common side effects are gastrointestinal, related to dose, and usually manageable. The serious risks are real, are printed on the FDA label, and are the reason these are prescription drugs rather than something you pick off a menu.

So the honest answer to “are GLP-1s safe” is always conditional: safe for whom, at what dose, and with what monitoring. This page walks through what the current FDA prescribing information actually says — including two things that changed in 2026 and one thing that did not change, despite a great deal of content claiming otherwise.

FDA labeling status on this page verified August 19, 2026, against the current prescribing information for Wegovy (rev. 06/2026), Zepbound (rev. 04/2026), Ozempic injection (rev. 05/2026), Mounjaro (rev. 4/2026), and oral semaglutide tablets (rev. 01/2026).

Key Takeaways

• FDA asked for the suicidal behavior and ideation warning to be removed from Saxenda, Wegovy, and Zepbound on January 13, 2026, after reviewing 91 placebo-controlled trials (107,910 patients) and a 2.2-million-patient real-world cohort. The removal now appears in the current Wegovy and Zepbound labels.
• There is no NAION or vision-loss warning in the US labels for Ozempic, Wegovy, Mounjaro, or Zepbound as of August 19, 2026. The UK regulator added one on February 5, 2026. Diabetic retinopathy — which is in the US labels — is a different condition.
• The boxed warning is about thyroid C-cell tumors seen in rodents. The labels themselves state that routine calcitonin blood testing and thyroid ultrasound are “of uncertain value” for screening, and may lead to unnecessary procedures.
• Dysesthesia — altered skin sensation — rises sharply with dose: 22% at Wegovy 7.2 mg injection versus 6% at 2.4 mg and 0.3% on placebo. Most patients have never heard of it.
• Certain people should not take these medications at all, and identifying them is a clinical evaluation, not a checkbox on an online form.

What “Safe” Actually Means for a Prescription Medication

No medication is safe in the abstract. A drug is safe when the expected benefit for a specific person outweighs the expected risk for that same person, at a dose they can tolerate, with follow-up that catches problems early.

For GLP-1 receptor agonists, the risk picture divides into three tiers: side effects that are common and usually manageable (nausea, vomiting, diarrhea, constipation, reflux, fatigue — dose-related, worst during escalation, generally improving, and the reason titration is slow); risks that are uncommon but serious and printed on the label; and a short list of absolute reasons not to use the drug at all.

Most public argument about GLP-1 safety happens in that middle tier, where absolute risks are small but not zero, and where the answer genuinely depends on the individual.

What FDA Removed in 2026: The Suicidality Warning

Direct answer: On January 13, 2026, FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy, and Zepbound, after concluding its evaluation did not identify an increased risk. That removal has since been made in the labels.

The warning existed because reports of suicidal thoughts in GLP-1 users prompted a safety review. That is pharmacovigilance functioning as designed: a signal appears, it gets investigated, and the investigation produces an answer. In this case the signal was not confirmed. FDA’s evaluation drew on:

• A meta-analysis of 91 placebo-controlled trials covering 107,910 patients (60,338 on a GLP-1 receptor agonist, 47,572 on placebo), which found no increased risk of suicidal ideation or behavior.
• A Sentinel System cohort study of 2,243,138 patients — roughly 1.16 million GLP-1 initiators compared with 1.08 million patients starting SGLT2 inhibitors, a different diabetes drug class — which found no increased risk of self-harm.
• A review of published observational studies, which FDA concluded did not support a causal relationship.

FDA’s own heading was unambiguous: “FDA’s Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications.” No elevated risk was found for depression, anxiety, irritability, or psychosis either.

Has the label change actually happened?

Yes — and this is worth verifying rather than assuming, because FDA requested the change; manufacturers implement it. We checked the current prescribing information directly:

• Wegovy (rev. 06/2026) lists under Recent Major Changes: “Suicidal Behavior and Ideation (5.10) … (Removed) 01/2026.” The subsection is gone from Warnings and Precautions.
• Zepbound (rev. 04/2026) lists “Suicidal Behavior and Ideation (Removed) 02/2026.” The word does not appear elsewhere in the label.

Saxenda was named in the same FDA request. We did not independently verify its current label revision for this article.

What the removal does not mean

A label change is a statement about populations, not about you. It means no excess risk was detectable across more than 100,000 randomized patients and more than two million real-world patients. It does not mean nobody ever experiences a mood change on these medications. Significant weight loss is a real life change, and depression and anxiety are common conditions that exist independently of any drug.

FDA’s patient guidance did not change on this point, and neither should yours: tell your clinician about new or worsening depression, unusual mood changes, or thoughts of self-harm. If you are in crisis, call or text 988 — the Suicide and Crisis Lifeline — now.

Vision, NAION, and What the US Label Actually Says

This is the area where current online content is least reliable, so here is the precise position.

Direct answer: As of August 19, 2026, there is no NAION warning, precaution, or adverse-reaction entry in the US prescribing information for Ozempic, Wegovy, Mounjaro, or Zepbound. The only eye-related labeling in those documents concerns diabetic retinopathy, which is a different condition.

NAION stands for non-arteritic anterior ischemic optic neuropathy — a sudden, usually painless loss of vision in one eye caused by reduced blood flow to the optic nerve head. It is rare and it is not the same thing as the retinal changes seen in diabetes.

Here is what has and has not happened:

• United Kingdom, February 5, 2026: The MHRA issued a Drug Safety Update concluding that semaglutide “may be very rarely associated with NAION” and added it to UK product information at a frequency of very rare — up to 1 in 10,000 people. The European review it drew on estimated roughly a twofold increase in relative risk in adults with type 2 diabetes, corresponding to about one additional affected person per 10,000 treated per year.
• United States, as of August 19, 2026: We searched the current US labels directly. Neither “NAION” nor “optic neuropathy” appears in the Ozempic (05/2026), Wegovy (06/2026), Mounjaro (4/2026), or oral semaglutide tablet (01/2026) prescribing information. US litigation on this question exists, but litigation is not a regulatory finding.

Diabetic retinopathy is the separate, genuinely labeled issue. The Ozempic label states that in a two-year trial of patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% of Ozempic-treated patients versus 1.8% on placebo — with the increase concentrated in patients who already had retinopathy at baseline (8.2% vs 5.2%) rather than those who did not (0.7% vs 0.4%). The mechanism is thought to relate to rapid improvement in blood sugar, recognized long before these drugs existed. Wegovy, Zepbound, and Mounjaro each carry their own diabetic retinopathy subsection directed at patients with type 2 diabetes or a retinopathy history.

The practical takeaway is the same either way: if you have diabetic eye disease, your treatment plan should include eye monitoring, and any sudden change in vision warrants urgent evaluation — not a wait-and-see approach, and not a search engine.

The Boxed Warning: Thyroid C-Cell Tumors

Direct answer: Every GLP-1 medication approved for weight management carries a boxed warning about thyroid C-cell tumors, based on findings in rodents. Human relevance has not been determined. The medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The Zepbound label states it plainly: in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and “it is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.” The semaglutide labels use parallel language.

That is a boxed warning built on an unresolved question, not on a demonstrated human harm — appropriate caution, and the reason the contraindication is written as a family-history question most patients have never been asked before.

The part patients consistently get wrong

Many people assume a boxed warning about thyroid tumors means they need an ultrasound before starting and a calcitonin blood test every few months. The labels say the opposite. Both the Wegovy and Zepbound prescribing information state, in nearly identical words: “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with [the drug].”

This is not the manufacturer minimizing anything. Calcitonin has a meaningful false-positive rate, thyroid nodules are extremely common and mostly harmless, and screening a low-risk population reliably generates biopsies, repeat imaging, and anxiety without finding disease — which is why the labels note that an elevated calcitonin value may itself lead to unnecessary procedures.

What actually protects you is the conversation: a careful personal and family history for medullary thyroid carcinoma and MEN 2 before the first prescription, and prompt evaluation if a neck mass, persistent hoarseness, difficulty swallowing, or shortness of breath develops during treatment.

The Full Set of Labeled Warnings

These are the Warnings and Precautions subsections as printed in the current US labels. Not every warning appears on every product — the differences are meaningful.

Pregnancy: these medications are not for use in pregnancy. The Wegovy label directs clinicians to discontinue it in pregnant patients using it for weight reduction, and the 2026 Standards of Care in Overweight and Obesity describe all approved obesity medications as contraindicated in pregnancy, advising that they be stopped at least two months before a planned pregnancy. If you are pregnant, trying to conceive, or your contraception plan changes, that is an immediate conversation with your prescriber.

What Changed for the Oral Forms in 2025 and 2026

Oral semaglutide labeling was updated substantially in October 2025 and January 2026 — a genuine change to the safety document that most content has not picked up. The current tablet label (rev. 01/2026) now includes:

• A severe gastrointestinal adverse reactions section. Severe GI reactions were reported in 0.6% at the 7 mg dose and 2% at the 14 mg dose, versus 0.3% on placebo. Those are the older Rybelsus strengths; the reformulated Ozempic tablets are not milligram-for-milligram equivalent (1.5 mg ≡ 3 mg, 4 mg ≡ 7 mg, 9 mg ≡ 14 mg), so read the strength on your bottle, not on the internet.
• Not recommended in patients with severe gastroparesis.
• Acute kidney injury due to volume depletion, expanded, and expanded pancreatitis counseling.
• Expanded gallbladder guidance — in a four-year cardiovascular outcomes trial, cholelithiasis was reported in 1.1% of tablet-treated patients versus 0.9% on placebo, and cholecystitis in 1.1% versus 0.7%.
• Postmarketing nervous system reports including dizziness, dysesthesia, dysgeusia (altered taste), and headache.

A tablet is not automatically a milder medication. It is the same molecule with different absorption and different administration requirements.

Dysesthesia: The Side Effect Almost Nobody Mentions

Direct answer: Dysesthesia — altered skin sensation, including tingling, burning, skin pain, or skin that feels unusually sensitive — occurs with semaglutide, increases with dose and blood level, and generally resolves on its own or with dose reduction.

The Wegovy label (rev. 06/2026) is explicit: dysesthesia and related altered skin sensations occurred in trials of both the injection and the tablet, and “the incidence of dysesthesia with WEGOVY increased with increasing dosage and drug levels in the blood.” The numbers show how steep that relationship is:

This matters for two reasons. A patient who develops an odd burning or tingling sensation on a higher dose, and has never been told this exists, will reasonably wonder whether something neurological is wrong. And it illustrates a principle running through this whole page: more drug is not automatically better drug. The 2026 Standards of Care make the same point, noting that the right long-term maintenance dose “may not necessarily be the maximum approved dose.”

The Other Side of the Ledger

A safety page that only lists risks is not an honest safety page. The FDA record also contains approved benefits reaching beyond weight itself.

• Wegovy injection carries an FDA-approved indication to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, and non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight. That indication rests on the SELECT trial. A drug approved to reduce cardiovascular events sits in a different evidentiary category from one merely shown not to increase them.
• Wegovy injection also carries an indication for noncirrhotic MASH with moderate-to-advanced liver fibrosis, granted August 15, 2025 under accelerated approval — approved on a surrogate endpoint and contingent on a confirmatory trial. That distinction should be stated, not glossed.
• Zepbound carries an indication for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside weight management.
• Mounjaro is not approved for cardiovascular risk reduction as of August 2026. Its labeled indication remains glycemic control in type 2 diabetes. If you have seen otherwise, it was not the label.

Who Should Not Take These Medications

Some of this is absolute, some requires judgment. It is not a self-assessment.

Contraindicated:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to the specific medication
• Pregnancy (and these should be stopped in advance of a planned pregnancy)

Requires careful individual evaluation before and during treatment:

• History of pancreatitis
• Known gallbladder disease
• Severe gastroparesis or significant gastrointestinal motility disorders (the oral semaglutide label specifically says not recommended in severe gastroparesis)
• Type 2 diabetes treated with insulin or a sulfonylurea, where doses commonly need adjusting
• Existing diabetic retinopathy
• Significant kidney disease, or any condition that makes dehydration more dangerous
• Breastfeeding
• A surgery, endoscopy, or procedure requiring anesthesia or deep sedation
• Older adults on multiple medications, where dehydration and drug interactions carry more weight
• History of an eating disorder

Notice how many of these are answered by history rather than by a lab test. That is the central point about GLP-1 safety: the screening that matters most is a conversation with someone who knows your record.

When to Talk to Your Doctor

Seek emergency care now for:

• Severe, persistent abdominal pain, especially radiating to the back, with or without vomiting — possible pancreatitis
• Signs of a severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing; widespread hives
• Sudden loss of vision or rapid worsening of vision in one or both eyes
• Vomiting or diarrhea severe enough that you cannot keep fluids down, or you stop urinating

Call your prescriber promptly — the same week — for:

• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes
• Nausea or vomiting that is not improving or is preventing you from eating and drinking normally
• A neck lump, persistent hoarseness, or difficulty swallowing
• Repeated low blood sugar episodes, particularly if you also take insulin or a sulfonylurea
• New or worsening depression, unusual mood changes, or thoughts of self-harm
• New tingling, burning, or altered skin sensation, especially after a dose increase
• Any change in vision, even gradual

Tell every clinician before a procedure. Any surgery, colonoscopy, endoscopy, or dental work involving deep sedation should be planned with your GLP-1 in the room. All of these labels carry a pulmonary aspiration warning, and your anesthesiologist needs to know.

Nothing on this page is a reason to start, stop, or change a medication on your own. Dose changes and discontinuations belong in a conversation with the clinician who prescribed the drug.

Scale Solutions & Coastal Georgia

Almost every warning on the FDA label has the same practical answer behind it: someone who knows your history, sees you regularly, and can be reached when something changes.

That is not an abstraction. It means the family history question about medullary thyroid carcinoma gets asked before the first prescription, not after. It means an insulin or sulfonylurea dose gets adjusted rather than left alone. It means that when a patient in Pooler picks up a stomach bug on a high dose, there is a physician to call about hydration before it becomes an acute kidney injury. It means a retiree in Hinesville with a scheduled procedure gets the anesthesia conversation handled in advance. And it means that when a headline claims FDA added a vision warning, someone can tell you what the label actually says today.

Scale Solutions provides physician-led medical weight management across Savannah, Chatham County, and Coastal Georgia — Pooler, Richmond Hill, Rincon, Hinesville, Statesboro, and the communities in between. The same practice that starts you on a medication should be the one watching what it does over the following year.

If you live in Savannah or anywhere in Coastal Georgia and something you read about GLP-1 safety has you concerned — about a symptom, a family history, an upcoming procedure, or a headline you cannot make sense of — you are welcome to reach out to us anytime. We are glad to answer questions, whether or not you are a patient.

Related: what the thyroid boxed warning actually says.

Related: how pancreatitis risk compares to the fear around it.

Related: gallbladder screening before and during treatment.

Related: what the SELECT trial showed about heart safety.

Related: managing the common GI side effects.

Related: additional considerations for adults over 60.

Related: check whether you may be a candidate.

Frequently Asked Questions

Did the FDA remove the suicide warning from Ozempic and Wegovy? FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy, and Zepbound on January 13, 2026, after finding no increased risk across 91 placebo-controlled trials (107,910 patients) and a 2.2-million-patient real-world cohort. The removal appears in the current Wegovy and Zepbound labels. FDA’s request named Saxenda, Wegovy, and Zepbound specifically — it did not name Ozempic. You should still report mood changes to your clinician.

Does semaglutide cause blindness? There is no NAION or vision-loss warning in the US prescribing information for Ozempic, Wegovy, Mounjaro, or Zepbound as of August 19, 2026. The UK regulator added NAION to its product information on February 5, 2026, classified as very rare — up to 1 in 10,000 people. The US labels do include diabetic retinopathy warnings, which describe a different condition. Any sudden vision change should be evaluated urgently regardless.

Do I need a thyroid ultrasound or calcitonin test before starting? The Wegovy and Zepbound labels state that routine calcitonin monitoring and thyroid ultrasound are “of uncertain value” for detecting medullary thyroid carcinoma in patients on these drugs, and may lead to unnecessary procedures. What matters more is a thorough personal and family history for MTC and MEN 2. Your own clinician may still order imaging for reasons specific to you.

Are GLP-1 medications safe long term? The long-term record is measured in years rather than decades, and it is reassuring rather than complete. Cardiovascular outcomes trials followed patients for multiple years, and semaglutide holds an FDA-approved indication to reduce major adverse cardiovascular events in a specific population. The honest position is that long-term data continue to accumulate and that the class remains under active post-marketing surveillance — as the 2026 label changes demonstrate.

Is the pill safer than the injection? Not inherently. Oral semaglutide is the same molecule, and its label was expanded in 2025 and 2026 to add severe gastrointestinal reactions, kidney injury from volume depletion, and a statement that it is not recommended in severe gastroparesis. Route of delivery changes convenience and absorption, not the underlying pharmacology.

What is the most preventable serious problem in real practice? Dehydration. Acute kidney injury from volume depletion — driven by vomiting and diarrhea — is a labeled warning on every one of these products. Patients who feel less thirst, eat less, and drink less while managing GI side effects can get behind on fluids quickly.

Can I take a GLP-1 if I’ve had pancreatitis or had my gallbladder removed? That requires individual evaluation. A prior episode of pancreatitis is a reason for careful discussion rather than an automatic disqualification, and neither is a prior cholecystectomy. This is the kind of decision that belongs with a clinician who has your full record.

Do I need to stop before surgery? Tell your surgical and anesthesia team well in advance that you take a GLP-1. All of these labels carry a pulmonary aspiration warning for general anesthesia and deep sedation. Guidance has shifted toward risk stratification rather than blanket discontinuation, and individual hospitals follow differing protocols — so this is a plan you make with your care team, not a rule you apply yourself.

Conclusion

The strongest thing that can be said about GLP-1 safety in 2026 is not that these medications are risk-free. It is that we know what the risks are, in more detail than for most drugs people take without a second thought — and that the system kept checking after approval. A suicidality warning went on because a signal deserved investigation, and came off when the investigation produced an answer. Labeling for the oral forms was expanded when new information warranted it. A vision question is being weighed differently by different regulators right now, and the responsible thing is to say so rather than pick the version that sounds better.

What no label can tell you is whether these medications are right for you. That depends on your thyroid history, your gallbladder, your kidneys, your other prescriptions, your surgical calendar, and how you tolerate the dose you are actually on.

If you are in Savannah or Coastal Georgia and want that question answered properly — by a physician who will look at your full history rather than a questionnaire — contact Scale Solutions. Bring the headline that worried you. We would rather talk through it with you than have you decide alone.

MEDICAL SOURCES & FURTHER READING

FDA 1. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication, January 13, 2026 (updated April 3, 2026). https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp 2. WEGOVY (semaglutide) injection and tablets — Full Prescribing Information. Novo Nordisk. Revised 06/2026. https://www.novo-pi.com/wegovy.pdf 3. ZEPBOUND (tirzepatide) injection — Full Prescribing Information. Eli Lilly and Company. Revised 04/2026. https://pi.lilly.com/us/zepbound-uspi.pdf 4. OZEMPIC (semaglutide) injection — Full Prescribing Information. Novo Nordisk. Revised 05/2026. https://www.novo-pi.com/ozempic.pdf 5. MOUNJARO (tirzepatide) injection — Full Prescribing Information. Eli Lilly and Company. Revised 4/2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4edc99a-ecdb-4a68-bcb4-69fbba2190e8&type=display 6. RYBELSUS / OZEMPIC (semaglutide) tablets — Full Prescribing Information. Novo Nordisk, NDA 213051. Revised 01/2026. https://www.novo-pi.com/ozempictablets.pdf 7. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — approved labeling, supplement 033. Revised 02/2026 (documents the removal of subsection 5.10). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf

Other regulators 8. UK Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Semaglutide (Ozempic, Rybelsus, Wegovy) — risk of non-arteritic anterior ischaemic optic neuropathy (NAION). February 5, 2026. https://assets.publishing.service.gov.uk/media/69847cb7468d351e1406b4d2/DSU_-Semaglutide_and_NAION-_5_Feb_2026.pdf

Clinical guidelines 9. Gudzune KA, et al.; American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Published January 13, 2026. DOI 10.2337/doci25-0008. Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12815056/

Peer-reviewed literature 10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. DOI 10.1056/NEJMoa2307563. — the trial supporting Wegovy’s FDA-approved cardiovascular indication.

Scale Solutions follows a published editorial policy for medical content. This article is for general education and is not a substitute for individual medical advice.